Mereo Biopharma Group PLC Share Price Today: Live Updates & Key Insights

Mereo Biopharma Group PLC share price today is $0.3338, up -5.18%. The stock opened at $0.3585 against the previous close of $0.3607, with an intraday high of $0.3734 and low of $0.3366.

Mereo Biopharma Group PLC Share Price Chart

Mereo Biopharma Group PLC

us-stock
To Invest in {{usstockname}}
us-stock

Mereo Biopharma Group PLC Share Price Performance

$0.3338 -0.0518(-5.18%) MREO at 23 Mar 2026 02:20 PM Biotechnology
Lowest Today 0.3366
Highest Today 0.3734
Today’s Open 0.3585
Prev. Close 0.3607
52 Week High 3.05
52 Week Low 0.20
Day’s Range: Low 0.3366 High 0.3734
52-Week Range: Low 0.20 High 3.05
1 day return -
1 Week return -13.45
1 month return -12.96
3 month return -84.75
6 month return -81.17
1 year return -85.97
3 year return -58.42
5 year return -91.48
10 year return -

Mereo Biopharma Group PLC Institutional Holdings

HHG PLC 10.24

Rubric Capital Management LP 9.62

683 Capital Management LLC 9.44

EcoR1 Capital, LLC 4.94

Mangrove Partners 4.90

Schonfeld Strategic Advisors LLC 3.83

Morgan Stanley - Brokerage Accounts 2.10

The Goldman Sachs Group Inc 1.49

Tejara Capital Ltd 1.20

UBS Asset Mgmt Americas Inc 1.20

UBS (Lux) EF Biotech (USD) P-acc 1.11

Balyasny Asset Management LLC 0.80

UBS Group AG 0.61

Monaco Asset Management 0.59

Atle Fund Management AB 0.48

Two Sigma Investments LLC 0.33

Logos Global Management LP 0.31

BlackRock Inc 0.28

Group One Trading, LP 0.28

Bank of America Corp 0.28

EntryPoint Capital LLC 0.25

HealthInvest Sustainable Healthcare E 0.23

iShares Genomics Immnlgy & Hlthcr ETF 0.14

HealthInvest S&M Cap Healthcare C 0.12

State Street® SPDR® S&P® Intl Sm Cp ETF 0.08

Virtus LifeSci Biotech Clinical Trls ETF 0.08

UBS Global Equity Biotech 0.08

Fidelity Nasdaq Composite Index 0.06

Forefront Tiresias Strategy 0.02

iShares Genomics Imnlgy & Hlthcr ETF CAD 0.00

Arctic Aurora Biotech Select N NOK Acc 0.00

Blackstone Alternative Multi-Strategy I 0.00

Northern Small Cap Core I 0.00

NT Quality SCC US Fund - L 0.00

NT Quality Small Cap Core 0.00

Mereo Biopharma Group PLC Market Status

Strong Buy: 6

Buy: 2

Hold: 0

Sell: 0

Strong Sell: 0

Mereo Biopharma Group PLC Fundamentals

Market Cap 57.40 M

PB Ratio 1.1918

PE Ratio 0.0

Enterprise Value 7.24 M

Total Assets 45.92 M

Volume 1826348

Mereo Biopharma Group PLC Company Financials

Annual Revenue FY23:10000000 10.0M, FY22:1507000 1.5M, FY21:36464000 36.5M, FY20:393000 0.4M, FY19:-122000 -0.1M

Annual Profit FY23:7426000 7.4M, FY22:2443000 2.4M, FY21:18556000 18.6M, FY20:-15954000 -16.0M, FY19:-23730000 -23.7M

Annual Net worth FY23:-29466000 -29.5M, FY22:-34196000 -34.2M, FY21:12725000 12.7M, FY20:-163628000 -163.6M, FY19:-34844000 -34.8M

Quarterly Revenue Q3/2025:0 0.0M, Q2/2025:500000 0.5M, Q1/2025:0 0.0M, Q3/2024:0 0.0M, Q2/2024:0 0.0M

Quarterly Profit Q3/2025:-1000 -0.0M, Q2/2025:368000 0.4M, Q1/2025:-271036 -0.3M, Q3/2024:0 0.0M, Q2/2024:-257288 -0.3M

Quarterly Net worth Q3/2025:-7024000 -7.0M, Q2/2025:-14616000 -14.6M, Q1/2025:-12887000 -12.9M, Q3/2024:-15001000 -15.0M, Q2/2024:-12255000 -12.3M

About Mereo Biopharma Group PLC & investment objective

Company Information Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom, the United States, and internationally. It develops Etigilimab, an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for use in the treatment of tumors. The company is also developing Navicixizumab, which has completed Phase 1b clinical trials for the treatment of the late line ovarian cancer; Acumapimod, a p38 MAP kinase inhibitor that is in Phase II clinical trials to treat acute exacerbations of chronic obstructive pulmonary disease; and Leflutrozole, an oral aromatase inhibitor, which is in Phase 2 trials for use in the treatment of hypogonadotropic hypogonadism. In addition, it develops rare disease product candidates, including Setrusumab, an antibody for the treatment of osteogenesis imperfecta; and Alvelestat, an oral small molecule that is in Phase II clinical trial to treat Alpha-1 anti-trypsin deficiency. The company has a license agreement with Feng Biosciences for the development and commercialization of navicixizumab; license agreement with ReproNovo for the development and commercialization of leflutrozole; and licensing agreement with AstraZeneca. Mereo BioPharma Group plc was incorporated in 2015 and is headquartered in London, United Kingdom.

Organisation Biotechnology

Employees 36

Industry Biotechnology

CEO Dr. Denise Vera Scots-Knight Ph.D.

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*

Take your next step

Talk to our investment advisor for stock recommendations
Left
Get expert assistance for portfolio management
Right

Mereo Biopharma Group PLC FAQs

What is the share price of Mereo Biopharma Group PLC today?

The current share price of Mereo Biopharma Group PLC is $0.3338.

Can I buy Mereo Biopharma Group PLC shares in India?

Yes, Indian investors can buy Mereo Biopharma Group PLC shares by opening an international trading and demat account with Motilal Oswal.

How to buy Mereo Biopharma Group PLC shares in India?

You can easily invest in Mereo Biopharma Group PLC shares from India by:

Can I buy fractional shares of Mereo Biopharma Group PLC?

Yes, many platforms allow you to buy fractional shares starting from as low as $1.

What is the market capitalization value of Mereo Biopharma Group PLC?

Mereo Biopharma Group PLC has a market cap of $57.40 M.

In which sector does Mereo Biopharma Group PLC belong?

Mereo Biopharma Group PLC operates in the Biotechnology sector.

What documents are required to invest in Mereo Biopharma Group PLC stocks?

To invest, you typically need:

What is the PE and PB ratio of Mereo Biopharma Group PLC?

The PE ratio of Mereo Biopharma Group PLC is N/A and the PB ratio is 1.19.